AI assistant
MEMPHASYS LIMITED. — Capital/Financing Update 2022
Aug 17, 2022
65314_rns_2022-08-17_7be8fe42-e8b7-4f5e-8c6d-4eb3ccbb9dc5.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Update Summary
Entity name
MEMPHASYS LIMITED.
Announcement Type
Update to previous announcement
Date of this announcement
18/8/2022
Reason for update to a previous announcement update to the capital raising timetable
Refer to next page for full details of the announcement
Proposed issue of securities
1 / 10
Proposed issue of securities
Part 1 - Entity and announcement details
==> picture [21 x 22] intentionally omitted <==
1.1 Name of +Entity
MEMPHASYS LIMITED.
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).
1.2 Registered Number Type Registration Number ABN 33120047556
1.3 ASX issuer code
MEM
1.4 The announcement is
==> picture [8 x 8] intentionally omitted <==
Update/amendment to previous announcement
1.4a Reason for update to a previous announcement
update to the capital raising timetable
1.4b Date of previous announcement to this update
17/8/2022
1.5 Date of this announcement
18/8/2022
1.6 The Proposed issue is:
==> picture [8 x 8] intentionally omitted <==
==> picture [8 x 8] intentionally omitted <==
A standard +pro rata issue (non-renounceable or renounceable) A placement or other type of issue
1.6a The proposed standard +pro rata issue is:
==> picture [8 x 9] intentionally omitted <==
- Non-renounceable
Proposed issue of securities
2 / 10
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Part 3 - Details of proposed entitlement offer issue
Part 3A - Conditions
3A.1 Do any external approvals need to be obtained or other conditions satisfied before the entitlement offer can proceed on an unconditional basis? No
Part 3B - Offer details
Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued
ASX +security code and description
MEM : ORDINARY FULLY PAID
Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Existing class
Will the proposed issue of this If the entity has quoted company +security include an offer of options, do the terms entitle option attaching +securities? holders to participate on exercise? No No
Details of +securities proposed to be issued
ASX +security code and description MEM : ORDINARY FULLY PAID
ISIN Code (if Issuer is a foreign company and +securities are non CDIs)
ISIN Code for the entitlement or right to participate in a non-renounceable issue (if Issuer is foreign company and +securities are non CDIs)
Offer ratio (ratio to existing holdings at which the proposed +securities will be issued)
The quantity of additional +securities For a given quantity of +securities to be issued held
1 9
Proposed issue of securities
3 / 10
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
What will be done with fractional Maximum number of +securities entitlements? proposed to be issued (subject to rounding) Fractions rounded up to the next 88,019,816 whole number
Offer price details for retail security holders
In what currency will the offer be What is the offer price per +security made? for the retail offer? AUD - Australian Dollar AUD 0.02000
Oversubscription & Scale back details
Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)? Yes
Describe the limits on over-subscription
Allocation of the Shortfall Shares will be at the discretion of the Board in conjunction with the Underwrite
Will a scale back be applied if the offer is over-subscribed? No
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Yes
Part 3C - Timetable
3C.1 +Record date
24/8/2022
3C.2 Ex date
23/8/2022
3C.4 Record date
24/8/2022
Proposed issue of securities
4 / 10
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
3C.5 Date on which offer documents will be sent to +security holders entitled to participate in the +pro rata issue 29/8/2022 3C.6 Offer closing date 7/9/2022 3C.7 Last day to extend the offer closing date 2/9/2022 3C.9 Trading in new +securities commences on a deferred settlement basis 8/9/2022 3C.11 +Issue date and last day for entity to announce results of +pro rata issue 14/9/2022 3C.12 Date trading starts on a normal T+2 basis 15/9/2022 3C.13 First settlement date of trades conducted on a +deferred settlement basis and on a normal T+2 basis 19/9/2022
Part 3E - Fees and expenses 3E.1 Will there be a lead manager or broker to the proposed offer? Yes 3E.1a Who is the lead manager/broker? Canaccord Genuity (Australia) Limited 3E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker? (a) a management fee of 2.0% of the gross proceeds raised under the Offer; and (b) a selling/underwriting fee of 4% of the gross proceeds raised from any Shortfall under the Offer placed by the Lead Manager. 3E.2 Is the proposed offer to be underwritten? Yes 3E.2a Who are the underwriter(s)? Canaccord Genuity (Australia) Limited 3E.2b What is the extent of the underwriting (ie the amount or proportion of the offer that is underwritten)? (a) a management fee of 2.0% of the gross proceeds raised under the Offer; and (b) a selling/underwriting fee of 4% of the gross proceeds raised from Shortfall under the Offer placed by the Lead Manager
Proposed issue of securities
5 / 10
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
3E.2c What fees, commissions or other consideration are payable to them for acting as underwriter(s)?
- (a) a management fee of 2.0% of the gross proceeds raised under the Offer; and
(b) a selling/underwriting fee of 4% of the gross proceeds raised from any Shortfall under the Offer placed by the Lead Manager
3E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated
Indices fall; Non-compliance with disclosure requirements; Misleading Prospectus; Restriction on allotment; ASIC application; Takeovers Panel; Hostilities; Authorisation, Indictable offence;
3E.2e Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed offer? Yes
3E.2e (i) What is the name of that party?
Alison Coutts
3E.2e (ii) What is the extent of their underwriting or sub-underwriting (ie the amount or proportion of the offer they have underwritten or sub-underwritten)?
$42,652
3E.2e (iii) What fee, commission or other consideration is payable to them for acting as underwriter or sub-underwriter?
fee of 1% of the value of Shares sub-underwritten (based on the Offer price of $0.02 per Share
3E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission? No
3E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer
Part 3F - Further Information
3F.1 The purpose(s) for which the entity intends to use the cash raised by the proposed issue
o continuing the commercialisation of the FelixTM System,
o undertaking FelixTM System clinical trials and other regulatory activities,
o continuing the development of other pipeline products with Uni of Newcastle
3F.2 Will holdings on different registers or subregisters be aggregated for the purposes of determining entitlements to the issue?
==> picture [8 x 9] intentionally omitted <==
No
3F.3 Will the entity be changing its dividend/distribution policy if the proposed issue is successful? No
3F.4 Countries in which the entity has +security holders who will not be eligible to participate in the proposed issue
the Offer is not being extended and Shares will not be issued to Shareholders with a registered address which is outside Australia or New Zealand.
Proposed issue of securities
6 / 10
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
3F.5 Will the offer be made to eligible beneficiaries on whose behalf eligible nominees or custodians hold existing +securities Yes
3F.5a Please provide further details of the offer to eligible beneficiaries
Nominees and custodians may not submit an Entitlement and Acceptance Form on behalf of any Shareholder resident outside Australia and New Zealand without the prior consent of the Company, taking into account relevant securities law restrictions
3F.6 URL on the entity's website where investors can download information about the proposed issue
https://www.memphasys.com/investor-relations/
3F.7 Any other information the entity wishes to provide about the proposed issue
3F.8 Will the offer of rights under the rights issue be made under a disclosure document or product disclosure statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)? Yes
3F.9 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:
The publication of a +disclosure document or +PDS involving the same class of securities as the +securities proposed to be issued that meets the requirements of section 708A(11) or 1012DA(11)
Proposed issue of securities
7 / 10
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Part 7 - Details of proposed placement or other issue
Part 7A - Conditions
7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis? No
Part 7B - Issue details
Is the proposed security a 'New Will the proposed issue of this class' (+securities in a class that is +security include an offer of not yet quoted or recorded by ASX) attaching +securities? or an 'Existing class' (additional No securities in a class that is already quoted or recorded by ASX)? Existing class
Details of +securities proposed to be issued
ASX +security code and description MEM : ORDINARY FULLY PAID Number of +securities proposed to be issued 80,000,000 Offer price details Are the +securities proposed to be issued being issued for a cash consideration? Yes In what currency is the cash What is the issue price per consideration being paid? +security? AUD - Australian Dollar AUD 0.02000
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Yes
Proposed issue of securities
8 / 10
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Part 7C - Timetable
7C.1 Proposed +issue date
24/8/2022
Part 7D - Listing Rule requirements
7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? No
7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? Yes
7D.1b ( i ) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?
80,000,000 ordinary shares representing 10.09% of placement capacity under listing rule 7.1
7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? No
7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? No
7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? No
7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? No
Part 7E - Fees and expenses
7E.1 Will there be a lead manager or broker to the proposed issue? Yes
7E.1a Who is the lead manager/broker?
Canaccord Genuity (Australia) Limited
7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?
Selling/underwriting fee of 4% of the gross proceeds raised from the Placement and the Offer Management fee of 2.0% of the gross proceeds raised under the Offer
7E.2 Is the proposed issue to be underwritten?
==> picture [8 x 8] intentionally omitted <==
No
Proposed issue of securities
9 / 10
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue
The Company agrees to reimburse the Canaccord for all reasonable out-of-pocket expenses incurred by the Lead Manager in connection with the Lead Manager Mandate and the Offer, including legal fees up to a maximum of $20,000
Part 7F - Further Information
7F.01 The purpose(s) for which the entity is issuing the securities
o continuing the commercialisation of the FelixTM System, o undertaking FelixTM System clinical trials and other regulatory activities, o continuing the development of other pipeline products with the University of Newcastle
7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No
7F.2 Any other information the entity wishes to provide about the proposed issue
7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:
The publication of a +disclosure document or +PDS involving the same class of securities as the +securities proposed to be issued that meets the requirements of section 708A(11) or 1012DA(11)
Proposed issue of securities
10 / 10